Loxapine
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00408 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 54 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | manic bipolar affective disorder | KG + DL |
| 2 | retinal dystrophy with or without extraocular anomalies | KG + DL |
| 3 | hydranencephaly (disease) | KG + DL |
| 4 | myopia X-linked | KG + DL |
| 5 | congenital disorder of glycosylation with defective fucosylation | KG + DL |
| 6 | Charcot-Marie-Tooth disease, demyelinating, type 1G | KG + DL |
| 7 | myopia 26, X-linked, female-limited | KG + DL |
| 8 | polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | KG + DL |
| 9 | syndromic myopia | KG + DL |
| 10 | atypical glycine encephalopathy | KG + DL |
| 11 | distal 17p13.3 microdeletion syndrome | KG + DL |
| 12 | attention deficit hyperactivity disorder, inattentive type | KG + DL |
| 13 | hydrops-lactic acidosis-sideroblastic anemia-multisystemic failure syndrome | KG + DL |
| 14 | anxiety disorder | KG + DL |
| 15 | attention deficit-hyperactivity disorder | KG + DL |
| 16 | Malan overgrowth syndrome | KG + DL |
| 17 | benign paroxysmal torticollis of infancy | KG + DL |
| 18 | agoraphobia | KG + DL |
| 19 | Phelan-McDermid syndrome | KG + DL |
| 20 | specific developmental disorder | KG + DL |
| 21 | faciodigitogenital syndrome | KG + DL |
| 22 | chondromyxoid fibroma | KG + DL |
| 23 | autism susceptibility 1 | KG + DL |
| 24 | autism spectrum disorder | KG + DL |
| 25 | gaze palsy, familial horizontal, with progressive scoliosis | KG + DL |
| 26 | asperger syndrome, susceptibility to | KG + DL |
| 27 | trichotillomania | KG + DL |
| 28 | amelocerebrohypohidrotic syndrome | KG + DL |
| 29 | childhood apraxia of speech | KG + DL |
| 30 | schizophreniform disorder | KG + DL |
| 31 | phobic disorder | KG + DL |
| 32 | mixed anxiety and depressive disorder | KG + DL |
| 33 | surfactant metabolism dysfunction, pulmonary | KG + DL |
| 34 | striatal degeneration, autosomal dominant | KG + DL |
| 35 | intellectual disability | KG + DL |
| 36 | 16q24.3 microdeletion syndrome | KG + DL |
| 37 | autism, susceptibility to | KG + DL |
| 38 | chromosome 15q11.2 deletion syndrome | KG + DL |
| 39 | occipital pachygyria and polymicrogyria | KG + DL |
| 40 | Tourette syndrome | KG + DL |
| 41 | dysthymic disorder | KG + DL |
| 42 | tic disorder | KG + DL |
| 43 | epsilon-trimethyllysine hydroxylase deficiency | KG + DL |
| 44 | REM sleep behavior disorder | KG + DL |
| 45 | transient tic disorder | KG + DL |
| 46 | psychotic disorder | KG + DL |
| 47 | psychosexual disorder | KG + DL |
| 48 | treatment-refractory schizophrenia | KG + DL |
| 49 | early-onset schizophrenia | KG + DL |
| 50 | hypotonia, infantile, with psychomotor retardation and characteristic facies | KG + DL |
(Showing top 50 of 54 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.